MIF inhibition interferes with the inflammatory and T cell-stimulatory capacity of NOD macrophages and delays autoimmune diabetes onset

PLoS One. 2017 Nov 2;12(11):e0187455. doi: 10.1371/journal.pone.0187455. eCollection 2017.

Abstract

Macrophages contribute in the initiation and progression of insulitis during type 1 diabetes (T1D). However, the mechanisms governing their recruitment into the islets as well as the manner of retention and activation are incompletely understood. Here, we investigated a role for macrophage migration inhibitory factor (MIF) and its transmembrane receptor, CD74, in the progression of T1D. Our data indicated elevated MIF concentrations especially in long-standing T1D patients and mice. Additionally, NOD mice featured increased MIF gene expression and CD74+ leukocyte frequencies in the pancreas. We identified F4/80+ macrophages as the main immune cells in the pancreas expressing CD74 and showed that MIF antagonism of NOD macrophages prevented their activation-induced cytokine production. The physiological importance was highlighted by the fact that inhibition of MIF delayed the onset of autoimmune diabetes in two different diabetogenic T cell transfer models. Mechanistically, macrophages pre-conditioned with the MIF inhibitor featured a refractory capacity to trigger T cell activation by keeping them in a naïve state. This study underlines a possible role for MIF/CD74 signaling pathways in promoting macrophage-mediated inflammation in T1D. As therapies directed at the MIF/CD74 pathway are in clinical development, new opportunities may be proposed for arresting T1D progression.

MeSH terms

  • Animals
  • Antigens, Differentiation, B-Lymphocyte / immunology
  • Diabetes Mellitus, Type 1 / immunology*
  • Female
  • Histocompatibility Antigens Class II / immunology
  • Humans
  • Lymphocyte Activation / immunology*
  • Macrophage Migration-Inhibitory Factors / antagonists & inhibitors*
  • Macrophages / immunology*
  • Mice
  • Mice, Inbred NOD
  • T-Lymphocytes

Substances

  • Antigens, Differentiation, B-Lymphocyte
  • Histocompatibility Antigens Class II
  • Macrophage Migration-Inhibitory Factors
  • invariant chain

Grants and funding

This work was supported by grants from the Flemish Research Foundation (Fonds Voor Wetenschappelijk Onderzoek Vlaanderen G.0649.08, G.0734.10 and 1.5.118.13N, a doctoral fellowhip to D.P.C., a postdoctoral fellowship to H.K., and a clinical fellowship to C.M.), the Belgium Program on Interuniversity Poles of Attraction initiated by the Belgian State (P6/40), the Katholieke Universiteit Leuven (GOA 2009/10 and GOA 14/010), the seventh Framework Program of the European Union with Natural Immunomodulators as Novel Immunotherapies for Type 1 Diabetes and the Diabetes Fonds Nederland (DFN Expert Center Beta Cell Immunoprotection) and N.V. Medtronic Belgium. B.S. was supported by the Strategic Research Program (SRP3, VUB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.